2023
Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsy
2022
Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy